



Bülent Güçyetmez
Aylin Ogan
Sevdinaz Rasimoğlu
Berrin Yalçın Güder
Evren Şentürk
İbrahim Bağcıvan
Hande Aygün
Ali Mert
Lütfi Telci

Red Cell Exchange Transfusion in Severe Falciparum Malaria and its Effects on Clinical Outcomes: A Case Report

Ciddi Falciparum Sıtmasında Eritrosit Süspansiyonu ile Kan Değişimi Kararı ve Klinik Seyir Üzerine Etkileri: Olgu Sunumu

Received/Geliş Tarihi: 07.03.2013
Accepted/ Kabul Tarihi: 01.04.2013
Journal of the Turkish Society of Intensive Care, published by Galenos Publishing.
Türk Yoğun Bakım Derneği Dergisi, Galenos Yayınevi tarafından basılmıştır.
ISSN: 1300-5804

Bülent Güçyetmez (✉), Aylin Ogan, Sevdinaz Rasimoğlu, Berrin Yalçın Güder
Intensive Care Unit, International Hospital, Istanbul, Turkey

Evren Şentürk, Lütfi Telci
Istanbul University Istanbul Faculty Of Medicine, Department of Anaesthesiology, Istanbul, Turkey

İbrahim Bağcıvan
International Hospital, Department of Internal Medicine, Istanbul, Turkey

Hande Aygün
International Hospital, Department of Infectious Diseases, Istanbul, Turkey

Ali Mert
Istanbul University Cerrahpasa Faculty of Medicine, Department of Infectious Diseases, Istanbul, Turkey,

E-posta: drbulentgucyetmez@yahoo.com
Tel.: +90 212 468 41 44

SUMMARY Red cell exchange transfusion (RCET) is a treatment option for severe falciparum malaria, which reduces the parasite load and toxemia. Pulmonary edema, metabolic changes, hyperkalemia, arrhythmia, hypocalcemia due to citrate toxicity, rebound hypoglycemia, hypothermia, anaphylactic reactions, hypotension or hypertension, thrombocytopenia, thrombo-embolism, coagulopathy, and necrotizing enterocolitis are the major acute phase RCET complications. In our case of severe falciparum malaria that was resistant to treatment; reduction in parasite load and sepsis was observed following RCET, but severe acute respiratory distress syndrome (ARDS) has developed.

Key Words: Severe falciparum malaria, red cell exchange transfusion, acute respiratory distress syndrome (ARDS)

ÖZET Eritrosit süspansiyonu ile kan değişimi (red cell exchange transfüzyon, RCET) ciddi falciparum sıtmasında parazit yükü ve toksemiye azaltmak için uygulanan bir tedavi seçeneğidir. Pulmoner ödem, metabolik değişiklikler, hiperkalemi, aritmi, sitrat toksisitesine bağlı hipokalsemi, rebound hipoglisemi, hipotermi, anaflaktik reaksiyonlar, hipotansiyon veya hipertansiyon, trombositopeni, trombo-embolizm, koagülopati ve nekrotizan enterokolit RCET uygulamasının erken döneminde görülebilen majör komplikasyonlardır. Tedaviye direnç gelişmiş ciddi falciparum tanılı olgumuzda, RCET sonrası parazit yükü ve septik tabloda gerileme olmasına rağmen ciddi akut respiratuar distres sendromu (ARDS) gelişmiştir.

Anahtar Kelimeler: Ciddi falciparum sıtması, eritrosit süspansiyonu ile kan değişimi, akut respiratör distres sendromu (ARDS)

Introduction

Immature trophozoites in infected erythrocytes are seen in peripheral blood smear in the form of ring formation (1,2). Red Cell Exchange Transfusion (RCET) is a treatment option considered in severe falciparum malaria in presence

of hyperparasitemia and organ failure or hyperparasitemia and resistance to treatment at over a rate of 10%, or hyperparasitemia alone at over a rate of 30%.^{3,4} Herein, we present our case of falciparum malaria with hyperparasitemia (25% involvement in blood smear) who underwent RCET because of severe septic shock; and ARDS was developed

despite an improvement in septic shock condition. We aimed to discuss benefits of RCET accordingly.

Case

A 35-year-old male patient admitted to the emergency department with complaints of fever, sore throat, and fatigue lasting for two days. The patient, who had been working in Nigeria, was reported to be conscious, cooperative, and spontaneously breathing in room air with blood pressure of 100/70 mmHg, heart rate 95/min, oxygen saturation (SpO₂) 98%, tympanic temperature 38.6°C, white blood cell count 5.81 x10³/mm³, platelet (PLT) count 38x10³/mm³, hemoglobin 15 g/dL, hematocrite 46%, aspartate aminotransferase 91 U/L, alanine aminotransferase: 91 U/L, gamma-glutamyl transferase 95 U/L, lactic dehydrogenase 480 U/L, total bilirubin 1.2 mg/dL, blood urea nitrogen 17 mg/dL and creatinine 1.0 mg/dL. The patient was diagnosed with falciparum malaria after plasmodium was observed in peripheral blood smear, and his parasite load was determined to be 25%. Mefloquine 1000 mg salt was administered to the patient followed by 500 mg 8 hours later and the patient was admitted to the internal medicine department. Hypotension, fever, PLT count 17x10³/mm³, tachypnea and increased in demand were developed in the patient under oral mefloquine treatment. Informed consent form was taken from the patient and the patient was admitted to the intensive care unit (Figure 1). Body temperature increased up to over 40°C within the first 20 hours at the intensive care unit. Due to tachypnea, dyspnea, and decrease in SpO₂ with a PaO₂/FiO₂ ratio of 137, the patient was put under invasive mechanical ventilation support in the 13th hour and with positive end expiratory pressure (PEEP) of 12 cmH₂O at controlled ventilation (PCV)



Figure 1. Radiological imaging- ICU income

mode. Therefore, mefloquine treatment was combined with doxycycline treatment. RCET decision was made since the patient was having a septic shock associated with 39°C body temperature, tachycardia, hypotension, PLT count 60x10³/mm³, non-improving SpO₂ (91%) and hypoxemia (PaO₂/FiO₂ of 113) had developed under the treatment and a parasite load was 25%. With the RCET performed between the 20th and the 24th hours of the patient's stay at the intensive care unit, 4000 ml of erythrocytes were separated and 12 U of erythrocyte suspension was administered. Body temperature was under control during the RCET but the SpO₂ (90%) and PaO₂/FiO₂ ratios (54) further decreased. During the 6-hour post-RCET period, hemodynamic stability was achieved, PaO₂/FiO₂ (137) and saturation (SpO₂:95%) increased (Figure 2), and the parasite load in the peripheral blood smear had decreased from 25% to 1%. There was ground glass opacity upon lung tomography at the 6th post-RCET hour (Figure 3) and PaO₂/FiO₂ ratios had not improved. Therefore, recruitment maneuver in the prone position was performed on the second day of his stay at the intensive care




Figure 2. First 30 hours and Daily Fever (max.), PaO₂/FiO₂ (max.), SpO₂ (min.) in ICU




Figure 3. CT- after RCET




Figure 4. Radiological imaging- ICU outcome

unit; was repeated after bronchoscopy on the 7th day and was extubated on the 11th day. The patient was spontaneous breathing and discharged on the 13th day on nasal oxygen support (Figure 2 and Figure 4).

Discussion

The clinical outcomes of falciparum malaria can include multi-organ failure. Complications of plasmodium nature and IV quinine resistance impact the choice of and response to treatment (5). Clinically, weakness, hyperpyrexia, anemia, hypoglycemia, thrombocytopenia, acute pulmonary edema, renal and hepatic dysfunction, cerebral involvement, metabolic acidosis, fluid-electrolyte imbalance, hemoglobinuria, hyperparasitemia, shock and disseminated intravascular coagulopathy (DIC) may be observed (6,7). Type of the pathogen, presence of complications, IV quinine resistance and the geographic region impact the treatment algorithm (8). Mefloquine treatment in non-complicated malaria (mefloquine 750 mg salt, followed by 6-12 hours later), and the quinine dihydrochloride treatment (was 20 mg/kg loading dose, followed by maintenance dose 10 mg/kg at 8 hours) are recommended to be combined with doxycycline, tetracycline, or clindamycin in severe malaria (9). In our case, mefloquine was combined with doxycycline due to development of thrombocytopenia, hypotension, and

respiratory failure. IV quinine could not be administered since it was not yet available in the market in Turkey. Ventricular arrhythmia, hypotension, hypoglycemia, and prolonged QT restrict the use of IV quinine (10). In cases of severe falciparum malaria, clinical deterioration is almost always observed along with cerebral involvement, renal dysfunction, and hyperparasitemia (4,5). Cerebral involvement in falciparum malaria increases mortality by 30%, while this rate can increase up to 80% with renal or respiratory failure (11). Hyperparasitemia and immune status also effect mortality (12). In our case, hyperparasitemia was observed without cerebral and renal involvement. The 25% parasite load seems to be the only cause of the serious clinical course of the case. In severe malaria, RCET is a treatment option considered in case of hyperparasitemia, organ failure, and resistance to treatment (13-15). Studies show that sepsis can decline with decreased parasite load through RCET (16-18). Our case had a parasite load of 25% and had developed septic shock within hours despite mefloquine and doxycycline treatment. Therefore, RCET treatment was chosen. RCET is usually administered within 4-5 hours via extracorporeal circulation and erythrocytes are transfused along with the patient's own plasma while infected erythrocytes are removed.¹⁹ The high fever pre-RCET is controlled during RCET as the fever declines with decreased parasite load. The SpO₂ and PaO₂/FiO₂ ratios, which were low before RCET did not improve as expected during RCET and has declined even further.

Consequently, mortality in severe falciparum malaria is high due to septic shock and organ failure. RCET proves to be an appropriate method to prevent mortality in presence of hyperparasitemia before organ failure develops. Parasite load significantly decreases and septic conditions decline through RCET. Absence of expected improvements in SpO₂ and PaO₂/FiO₂ ratios after RCET is considered as a sign that extracorporeal circulation and the massive transfusion has worsened the acute respiratory distress syndrome (ARDS). Severe ARDS can prolong the intensive care and mechanic ventilation duration.

In conclusion, we recommend that in a severe falciparum malaria case with <30% hyperparasitemia without renal and cerebral involvement, despite the risk of severe ARDS development risk, RCET should be considered as early as possible by close monitoring by clinical findings.

References

1. World malaria situation in 1994. Part I. Population at risk. *Wkly Epidemiol Rec* 1997;72:269-74.
2. Triglia T, Chen L, Lopaticki S, Dekiwadia C, Riglar DT, Hodder AN, et al. Plasmodium falciparum Merozoite invasion is inhibited by antibodies that target the PfRh2a and b binding domains. *PLoS Pathog* 2011;7(6):e1002075.
3. Mehta SR, Das S. Management of malaria: recent trends. *J Commun Dis* 2006;38:130-8.
4. Watanaboonyongcharoen P, Park YA, Poisson JL, Brecher ME. Rapid increases in parasitemia following red cell exchange for malaria. *J Clin Apher* 2011;26:315-9.

5. Shanbag P, Juvekar M, More V, Vaidya M. Exchange transfusion in children with severe falciparum malaria and heavy parasitaemia. *Ann Trop Paediatr* 2006;26:199-204.
6. Greenberg AE, Lobel HO. Mortality from *Plasmodium falciparum* malaria in travelers from the United States, 1959 to 1987. *Ann Intern Med* 1990;113:326-7.
7. White NJ. The treatment of malaria. *N Engl J Med* 1996;335:800-6.
8. From Centers for Disease Control and Prevention. Guidelines for treatment of malaria in the United States. <http://www.cdc.gov/malaria/resources/pdf/treatmenttable.pdf> Accessed on October 2012.
9. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, Seventh edition, New York: Churchill Livingstone Elsevier, 2010: 3452 Table 275-3.
10. Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster. *Trans R Soc Trop Med Hyg* 2000;94 Suppl 1:S1-90.
11. Mordmuller B, Kremsner PG. Hyperparasitemia and blood exchange transfusion for treatment of children with falciparum malaria. *Clin Infect Dis* 1998;26:850-2.
12. Boctor FN. Red blood cell exchange transfusion as an adjunct treatment for severe pediatric falciparum malaria, using automated or manual procedures. *Pediatrics* 2005;116:592-5.
13. Centers for Disease Control and Prevention (CDC). Availability and use of parenteral quinidine gluconate for severe or complicated malaria. *MMWR Morb Mortal Wkly Rep* 2000;49:1138-40.
14. Zucker JR, Campbell CC. Malaria. Principles of prevention and treatment. *Infect Dis Clin North Am* 1993;7:547-67.
15. Tejura B, Sass DA, Fischer RA, Daskal I, Eiger G. Transfusion-associated falciparum malaria successfully treated with red blood cell exchange transfusion. *Am J Med Sci* 2000;320:337-41.
16. Phillips P, Nantel S, Benny WB. Exchange transfusion as an adjunct to the treatment of severe falciparum malaria: Case Report and Review. *Rev Infect Dis* 1990;12:1100-8.
17. Powell VI, Grima K. Exchange transfusion for malaria and Babesia infection. *Transfus Med Rev* 2002;16:239-50.
18. Shelat SG, Lott JP, Braga MS. Considerations on the use of adjunct red blood cell exchange transfusion in the treatment of severe *Plasmodium falciparum* malaria. *Transfusion* 2010;50:875-80.
19. Laloo DG, Shingadia D, Pasvol G, Chiodini PL, Whitty CJ, Beeching NJ, et al. UK malaria treatment guidelines. *J Infect* 2007;54:111-21.